Iodine[131I] Metuximab

碘[131I]美妥昔单抗

Report date: 2025/09/04 17:54:00

Base Information

Drug NameIodine[131I] Metuximab
Drug Alias NameLicartin利卡汀
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[6] 
Mechanisms of ActionAnti-CD147Ionising radiation emitters
TargetsBasigin
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsCarcinoma, Hepatocellular
Approved Indications in ChinaCarcinoma, Hepatocellular
Original Approved Country/TerritoryMainland China
Original Approved Date2006/10/12
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesChengdu Huasun Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesChengdu Huasun Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeL01XC
Related LinksN/A